









The follow-up survey of medicinal drugs associated with QT prolongation, and a new software for 
avoidance and early recognition of drug-induced QT prolongation.
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ABSTRACT
In recent years, the mechanisms that cause congenital and secondary long QT syndrome have been elucidated in 
considerable detail. We have attempted to determine of treatment courses for individual patients when it is necessary 
to administer medicines associated with QT prolongation. Therefore we decided to conduct a follow-up survey of these 
medicines, and aim to develop a software for avoidance and early recognition of drug-induced QT prolongation in 
association with cardiovascular internal medicine at our hospital.
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1　緒　　　言
　医薬品による重篤な循環器系副作用として「QT延











































































































補正 QT時間（QTc） 異常 QT延長の判定
QTc≦ 0.45 なし
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